BioMerieux shares slump on 'bad' sales miss, outlook cut

Biomerieux SA

23/04/2026 08:37

** Shares in bioMerieux BIOX.PA fall 14% after the company cut its 2026 full-year guidance, after estimates-missing Q1, citing a sharp decline in respiratory testing activity and persistent pressures in China

** The stock is heading for its worst day in 6 years if losses persist

** The diagnostics group now expects organic revenue growth of 3-5% (prev.: 5-7%), with operating profit growth revised to 0-10% (prev.: at least 10%)

** Kepler Cheuvreux and RBC also point to Q1 sales at 983.6 million euros ($1.15 billion) 'badly' missing the consensus estimates

** TP ICAP Midcap notes that the underperformance stems from a markedly milder respiratory season, ongoing hospital budget constraints in China, and a still-cautious equipment market, rather than any deterioration in the company's structural growth drivers

** The stock, which touches its lowest price since Nov. 2019, sits at the very bottom of the SBF120 index .SBF120

($1 = 0.8545 euros)

(Reporting by Clement Martinot)

((Clement.Martinot@thomsonreuters.com;))